EG 427 expands Series A closing to 18m
Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at 18m raising additional 5m in the final closing.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Seed money for unique topical hair growth inducer
/in News/by Thomas GabrielczykMallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.
Evotec earns US$40m in global licence deal with BMS
/in News/by Thomas GabrielczykGerman CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
Nanobiotix SA licences NBTXR3 to J&J
/in News/by Thomas GabrielczykParis-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.
Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
/in News/by Thomas GabrielczykExeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its 24m (US$26m) Series A financing to advance the clinical development […]
Dutch go first: pre-approval tastings of cultivated meat & seafood in the Netherlands
/in News/by Thomas GabrielczykIt is just announced that it will soon be possible to taste farmed meat and seafood in the Netherlands under controlled conditions. The Dutch government, in collaboration with cultured meat […]
EU Regulation of Genome Editing in Plants not yet a law
/in News/by Thomas GabrielczykA long-awaited draft regulation from the EU Commission’s DG Sante to deregulate the authorisation, risk assessment and labelling of a whole range of new genetically modified organisms (GMOs) has been […]
Dutch NLC has 20m in first close of new Health Impact Fund
/in News/by Thomas GabrielczykDutch venture builder NLC has announced a 20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s […]
French Carthera closes 37.5m Series B financing round
/in News/by Thomas GabrielczykCarthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its 37.5m […]